WHO guideline development group meeting - Infant feeding in areas of Zika virus transmission

The World Health Organization (WHO) is committed to driving public health impact in every country, ensuring healthy lives and promoting well-being for all at all ages. WHO’s normative, data, and research and innovation activities drive the creation of global public goods. This work has been included as one of the WHO Global Public Health Goods for country impact and aims to support regional and country offices work and to help WHO Member States and their partners to make evidence-informed decisions on the appropriate actions in their efforts to improve access to quality essential health services, support countries to be prepared for health emergencies, and address the determinants of health. It will also help in increasing capacity in the countries to respond to their needs on preparedness on Zika virus infections and to prioritize essential actions in national health policies, strategies and plans.

As part of the key mandate of WHO to develop technical normative guidance on public health programmes and novel technologies, WHO convened a Guideline Development Group for the update of the current WHO Infant feeding in areas of Zika virus transmission. This guideline was developed, first as interim advice and then as a rapid advice guideline during the outbreak.

The purpose of this guideline is to provide a recommendation to guide governments, ministries of health, policy-makers and health-care workers in regions affected by transmission of Zika virus, in the development of local and national protocols and policies on infant feeding, including breastfeeding practices in areas of Zika virus transmission, and their implementation.

A final guideline development group meeting is planned by teleconference, with the following objectives:

  • To examine the Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence-to-decision profiles or other assessments of the quality of the evidence used to inform the recommendations and provide input;
  • To interpret the evidence, with explicit consideration of the overall balance of benefits and harms;
  • To formulate recommendations and determining their strength considering benefits, harms, values and preferences, feasibility, equity, ethics, acceptability, resource requirements and other factors, as appropriate;
  • To define implications for further research and gaps;
  • To discuss implementation and evaluation considerations of the guideline.

Join the event via videoconference.

9 December 2019 (14:30 – 17:00 CET) via videoconference

10 December 2019 (09:30 – 12:30 CET) via videoconference